Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AMLGlobeNewsWire • 12/13/22
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022GlobeNewsWire • 12/01/22
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022GlobeNewsWire • 11/10/22
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)GlobeNewsWire • 11/10/22
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022GlobeNewsWire • 11/03/22
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022GlobeNewsWire • 10/11/22
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
Cellectis Announces Participation in Four Upcoming Investor Conferences in SeptemberGlobeNewsWire • 09/01/22
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of DirectorsPRNewsWire • 09/01/22
Cellectis S.A. (CLLS) CEO Andre Choulika on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022GlobeNewsWire • 08/04/22
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell MalignanciesGlobeNewsWire • 08/01/22
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved PersistenceGlobeNewsWire • 06/30/22
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of DirectorsGlobeNewsWire • 06/28/22
Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 28, 2022GlobeNewsWire • 06/28/22
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCTGlobeNewsWire • 05/16/22
Cellectis S.A.'s (CLLS) CEO Andre Choulika on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022GlobeNewsWire • 05/12/22